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ABSTRACT 
EXAMINING THE ASSOCIATION BETWEEN PSYCOTROPIC MEDICATION 
USAGE AND SUICIDAL DESIRE AND RISK 
by Brittney LeAnn Assavedo 
December 2015 
The primary aim of this study was to examine the relationship between 
components of suicidal desire and psychotropic medication.  Specifically, the usage of 
psychotropic medication, the usage of specific classes of psychotropic medications and 
the amount of psychotropic medication utilized, and differences in feelings of perceived 
burdensomeness, thwarted belongingness, and overall suicide risk were examined.  The 
present study utilized pre-collected data consisting of 225 patients with substance use 
disorder, who are undergoing residential treatment for substance dependence.  It was 
posited that individuals utilizing psychotropic medications would exhibit higher mean 
levels of thwarted belongingness, perceived burdensomeness, and suicide risk relative to 
individuals not utilizing psychotropics and that individuals utilizing multiple 
psychotropic medications would exhibit higher suicidal desire and risk than individuals 
utilizing zero or one psychotropic medication. Additionally, it was posited that 
individuals utilizing antipsychotics would exhibit higher suicidal desire and risk than 
individuals utilizing any other type of psychotropic medication.  For all hypotheses, it 
was posited that such effects would occur above and beyond severity of psychopathology 
and substance use.  Results indicated a significant difference in suicide risk between 
individuals utilizing a psychotropic and individuals not utilizing a psychotropic.  
Additional exploratory analyses indicated a significant difference in levels of perceived 
 iii 
burdensomeness between individuals utilizing an antidepressant and individuals utilizing 
any other type of psychotropic besides an antidepressant.  Overall, results suggest that the 
use of psychotropic medication may increase the risk for suicide.  These findings 
highlight the need for routine suicide risk assessments for patients utilizing psychotropic 
medications.   
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 CHAPTER I 
INTRODUCTION 
Suicide is a significant public health concern in the U.S., serving as the tenth 
leading cause of death in 2013 (Centers for Disease Control and Prevention [CDC], 
2015).  A systematic review examining 15,629 cases of suicide in the general population 
between 1959 and 2001 suggested that 98% of individuals who died by suicide had a 
diagnosable mental disorder (Bertolote & Fleischmann, 2002).  Indeed, mental illness is a 
known risk factor for suicide, and suicidality is often treated through interventions aimed 
at addressing specific mental disorders.   
One approach to intervention commonly utilized for treating suicidal individuals 
is psychopharmacology, which can include numerous classes of drugs targeting a wide 
range of mental disorders; however, the evidence regarding the suicide prevention 
capabilities of psychotropic medications is mixed (Ernst & Goldberg, 2004).  For 
example, Rissanen et al. (2012) found that individuals taking antipsychotics for longer 
periods of time exhibited more suicidal ideation relative to individuals taking 
antipsychotics for shorter periods of time, even after accounting for symptoms of 
depression and anxiety.  Additionally, accounting for other psychiatric symptoms, the 
dosage of antipsychotic medication was significantly associated with suicidal ideation 
among individuals with non-psychotic diagnoses, such that higher doses were correlated 
with more suicidal ideation.  No consistent mechanism has been proposed for the studies 
mentioned above, further underscoring the inconsistency in the evidence for suicide-
related outcomes with respect to pharmacological treatment.   
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In addition to their association with suicidal ideation, psychotropics also 
potentially play a role in suicidal behavior.  Succeeding unspecified and medicinal 
substances, psychotropic medications are the most common agent utilized for intentional 
overdoses, which is the most common method of suicide attempt and self-inflicted injury 
among individuals requiring an Emergency Department visit as a result of such incidents 
(Ting, Sullivan, Boudreaux, Miller, & Camargo, 2012).  In 2011, benzodiazepines, 
antidepressants, and antipsychotics were utilized in approximately 62% of suicide 
attempts (Substance Abuse and Mental Health Services Administration, 2013).  Indeed, 
many psychotropic medications are labeled with a black box warning indicating potential 
risk of suicidal ideation or behavior for consumers (e.g. antidepressants, antiepileptics, 
Atomoxetine; Hassan, 2012).  Although prior studies have established the existence of a 
relationship between psychotropic medication and suicidality, research examining the 
nature of such a relationship is lacking; thus, empirical research investigating 
mechanisms and relevant contextual factors of psychotropic medication use associated 
with suicidality is essential for prevention of problematic outcomes and mitigation of 
consequences.   
One theoretical framework that may provide a method for understanding the 
nature of the relationship between psychotropic medications and suicidality is the 
interpersonal-psychological theory of suicidal behavior (IPTS; Joiner, 2005).  The theory 
posits that, in addition to the ability to die by suicide, an individual must possess a desire 
for suicide in order to enact lethal self-harm.  This desire for suicide is comprised of the 
simultaneous presence of two psychological states: perceived burdensomeness (PB) and 
thwarted belongingness (TB).  PB is an individual’s sense that he/she is a burden and 
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liability to family, friends, and/or society and the belief that one’s death is worth more to 
others than their continued life.  TB is an individual’s sense that he/she lacks meaningful 
connections with others.  
As suggested by Van Orden et al.’s (2010) hierarchical latent variable model, PB 
is comprised of a belief of liability and cognitions of self-hatred.  In this model, factors 
such as low self-esteem, shame, and unemployment result in feelings of PB.  The 
hierarchical latent variable model also suggests that TB is comprised of both loneliness 
and the absence of reciprocally caring relationships.  In this model, factors such as low 
social support, living alone, divorce, and social withdrawal result in feelings of TB.  A 
longitudinal study examining factors associated with psychotropic medication use at three 
time points within 17 years found that non-clinical characteristics predicted psychotropic 
medication use (Colman, Croudace, Wadsworth, & Jones, 2008).  Specifically, 
unemployment and lack of social support were associated with the use of antidepressants, 
anxiolytics, and hypnotics above and beyond the effects of the severity of 
psychopathology.  Unemployment significantly predicted psychotropic medication use at 
both time 1 and time 3; whereas, living alone, divorce and separation significantly 
predicted psychotropic medication use at time 3.  
Although several psychotropic medications are efficacious in the reduction of 
symptoms associated with particular psychopathological disorders, the use of these 
medications is often accompanied by adverse side effects (Murray, 2006; Ponterotto, 
1985).  Neurological disorders, confusion and disorientation, hallucinations, anxiety, 
depression, irritability, hostility, and anger have been associated with the use of 
benzodiazepines (Maxmen & Ward, 1995).  Antidepressants, specifically Selective 
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Serotonin Reuptake Inhibitors, have been reported to induce extrapyramidal symptoms 
such as akathaisia, dystonia, parkinsonism, and tardive dyskinesia (Leo, 1996).  
Increasing incidence of tardive dyskinesia was found to be associated with antipsychotic 
use over time (Glazer, 2000).  In a clinical sample of 362 adults, tardive dyskinesia was 
experienced by approximately 32% of individuals using antipsychotics for 5 years or less, 
57% using antipsychotics for 10 to 15 years, and 68% with 20 to 25 years of use.  In a 
study examining the regional brain activity of participants performing cognitive tasks 
succeeding treatment with mood stabilizers, results indicated that lithium and valproate 
caused cognitive impairments in individuals with no previous consumption of mood 
stabilizers (Bell, Willson, William, Dave, & Silverstone, 2005).   
Psychopharmacotherapy is often negatively stereotyped by individuals whom are 
unfamiliar with psychotropics, as one study found that individuals who had never utilized 
a psychotropic medication displayed significantly more negative attitudes towards and 
beliefs about psychotropic medication than either psychiatric or substance abuse 
outpatients (Fife, Ketzenberger, & Olson, 2012).  Similarly, upon examination of public 
opinions and beliefs regarding treatment of depression, Ozmen and colleagues (2005) 
found that the public considered pharmacotherapy an ineffective treatment for 
depression.  Furthermore, among the 213 participants, 62.1% believed that antidepressant 
treatment may result in addiction.   
In concordance with the negative view, stigmatization is often associated with 
psychopharmacology.  A study investigating stigmatization among adolescents utilizing 
psychiatric medication discovered thematic constructs that commonly emerged among 
such adolescents (Kranke, Floersch, Townsend, & Munson, 2009).  Adolescents taking 
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antipsychotic medication often felt a sense of shame associated with taking medication.  
Furthermore, adolescents perceiving non-acceptance from peers resulting from 
medication usage withdrew from peer interactions.  Additionally, a study examining 
patients’ personal experiences in regards to medication-induced stigmas discovered that 
patients with schizophrenia receiving medication treatment felt most stigmatized in areas 
of employment due to side effects of medication (e.g. others perceive work performance 
as being impaired; Novak & Švab, 2009).  Examining the perception of stigma among 
outpatients receiving antidepressants, Interian, Martinez, Guarnaccia, Vega, and Escobar 
(2007) found that the use of antidepressants was associated with negative attributes such 
as weakness and inability to cope with problems. 
The primary aim of the study is to investigate the association between 
psychotropic medication usage and suicidal desire and risk in a sample of adults 
receiving residential treatment for substance use disorders.  Given the adverse side effects 
of psychotropic medications and the stigmatizing effects associated with their usage, we 
hypothesize that individuals utilizing psychotropic medications will exhibit higher mean 
levels of PB, TB and suicide risk relative to individuals not utilizing psychotropics, above 
and beyond the effects of the severity of psychopathology.  Additionally, we posit that 
individuals utilizing multiple psychotropic medications will exhibit higher mean levels of 
PB, TB and suicide risk in contrast to individuals utilizing one or zero psychotropic 
medication, again controlling for severity of psychopathology.  Finally, we hypothesize 
that individuals utilizing antipsychotics will exhibit higher mean levels of PB, TB, and 
suicide risk than individuals utilizing psychotropic medications from any other 
classification (i.e. antidepressants, anxiolytics, or mood stabilizers).  Here again, we will 
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control for severity of psychopathology.  Effective mental health treatment for 
psychological disorders such as depressive, bipolar spectrum, and schizophrenic 
disorders often involves pharmacological therapy (e.g. Baghai et al., 2011; Culver, 
Arnow, & Ketter, 2007; Marder, 2000), and results consistent with hypotheses would 
suggest that individuals prescribed such medications may experience elevated levels of 
suicidal desire and risk; therefore, suggesting the need for routine suicide risk assessment 
in such individuals.  The proposed study does not intend to advocate against the use of 
psychopharmacology, but rather suggests closer monitoring of individuals utilizing 
psychotropic medication.  Although not all individuals utilizing such medication 
experience an increased risk for suicide, some individuals may experience increases in 
certain elements of risk.  Understanding the nature of the relationship between 
psychotropic medication and suicidality may allow for the reduction of risks in such 
individuals.   
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CHAPTER II 
 
METHOD 
Participants 
Participants included 225 patients with substance dependence (50.2% male) 
undergoing treatment in a residential Substance Use Disorder (SUD) treatment facility.  
Participants ranged in age from 18 to 65 years (Mage = 34.36).  Regarding participant 
ethnicity:  59.6% identified as White, 36.4% as African American, 1.3% as 
Hispanic/Latino, and 1.3% identified as another racial/ethnic background.  Regarding 
participants’ educational attainment:  27.1% had not completed high school or received a 
GED, 33.7% received a high school diploma or GED, and 8.8% graduated from college.  
Demographic information is included in Table 1.  Inclusion criteria for the current study 
consisted of information pertaining to the use of a psychotropic medication (presence 
versus absence) and, for those who endorsed currently taking psychotropic medications, 
the name of the psychotropic medication(s) being utilized.  Approximately half of the 
participants (n =112) were utilizing some form of prescribed psychotropic medication:  
36% utilized an antidepressant, 11% utilized an anxiolytic, 11% utilized a mood 
stabilizer, and 10% utilized an antipsychotic.  Additionally, 32.4% utilized medication 
from a single class of psychotropics, 13.8% utilized medication from two classes of 
psychotropic medication, and 2.7% utilized medication from three classes of 
psychotropic medication (see Table 2).   Risk for suicide was diverse within this sample, 
with majority of the sample (58.7%) endorsing at least a low risk for suicide and 38.7% 
endorsing no risk for suicide.   
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Table 1 
Demographic Information 
 
Race N = 222 Relationship Status N = 221 
White/Caucasian 59.6 Single 60.0 
Black/African American 36.4 Living with a partner 12.4 
Asian/Southeast Asian 0.4 Married but separated 10.7 
Hispanic/Latino 1.3 Married 15.1 
Native American 0.9   
Education N = 221 Income N = 218 
Less than High School 27.5 0 - 19,999 65.3 
High School Graduate/G.E.D.  33.7 20,000 - 39,999 14.7 
Some College 22.7 40,000 - 59,999 7.6 
College Graduate 6.2 60,000 - 79,999 4.0 
Some Graduate School 1.3 80,000 - 99,999 1.7 
Graduate or Professional Degree 1.3 100,000 or more 3.6 
 
 
Table 2 
Psychotropic Medication Information 
 
Variable Percentage (N = 225) 
Number of Psychotropic Medications   
0 51.1 
1 29.8 
2 14.2 
3 4.0 
4 0.4 
5 0.4 
  
Number of Psychotropic Classes   
0 51.1 
1 32.4 
2 13.8 
3 2.7 
  
Class of Psychotropic Medication Used  
Antidepressant 36.0 
Antipsychotic 10.2 
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Table 2 (continued). 
 
Variable Percentage (N= 225) 
Anxiolytic 11.1 
Mood Stabilizer 10.7 
 
Table 3 
Diagnostic Information 
DSM-IV Diagnosis Percent of Individuals with Diagnosis 
Generalized Anxiety Disorder 32.0 
Panic Disorder without Agoraphobia 24.9 
Posttraumatic Stress Disorder 24.9 
Social Phobia 23.1 
Antisocial Personality Disorder 38.7 
Borderline Personality Disorder 33.3 
Obsessive-Compulsive Personality Disorder 12.4 
Anorexia Nervosa 0.4 
Bulimia Nervosa 7.6 
Major Depressive Episode 25.8 
 
Measures 
Diagnostic and Clinical Interviews 
Substance Use Disorders.  The Structured Clinical Interview for Diagnostic and 
Statistical Manual of Mental Disorders, fourth edition (DSM-IV), Axis I Disorders 
(SCID-I/P; First, Spitzer, Gibbon & Williams, 1996) is a structured diagnostic interview 
assessing both current and lifetime DSM-IV Axis I disorders.  In the current study, the 
SCID-I/P was used to assess SUDs.  The SCID-I/P has demonstrated adequate inter-rater 
and test-retest reliability (Lobbestael, Leurgans, & Arntz, 2011).  Diagnostic frequencies 
are included in Table 3.   
Axis I Disorders.  The Mini International Neuropsychiatric Interview, Version 6.0 
(MINI; Sheehan et al., 2009) is a short structured diagnostic interview assessing current 
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DSM-IV Axis I disorders.  In the current study, the MINI was used to assess DSM-IV 
Axis I disorders, with the exclusion of posttraumatic stress disorder (PTSD) and SUDs.  
The MINI has demonstrated adequate reliability and validity in its assessment of 
psychiatric disorders, as well as strong test-retest and inter-rater reliability (Sheehan et 
al., 1997). 
Predictors 
Psychotropic Medication Usage.  Participants were asked, “Are you currently 
taking any medications for a psychiatric disorder?”  Answers were structured as yes 
versus no.  Responses were coded as 0 if participants did not endorse the use of a 
psychotropic medication, and as 1 if participants endorsed the use of a psychotropic 
medication.   
Number of Psychotropic Medications.  Participants who endorsed the use of 
psychotropic medications were asked to provide the names of the psychotropic 
medications currently being used.  Researchers verified if the medication name provided 
was actually a psychotropic, and responses were coded on the basis of the number of 
psychotropic medication names provided.  Responses ranged from 1 (use of a single 
psychotropic medication) to 5 (use of five psychotropic medications).   
Antipsychotic Usage. Based on the names of the psychotropic medications 
provided by participants each medication was coded into its respective classification (i.e. 
antidepressant, anxiolytic, antipsychotic, or mood stabilizer).  Medications were coded as 
1 if the medication was within the class and 0 if the medication was not in that class.   
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Outcomes 
Perceived Burdensomeness and Thwarted Belongingness.  The Interpersonal 
Needs Questionnaire-10-Item Version (INQ-10; Van Orden, Cukrowicz, Witte, & Joiner, 
2012) is a self-report questionnaire assessing the components comprising suicidal desire 
as conceptualized by the IPTS.  Items are scored on a Likert scale ranging from 1 (Not at 
all true for me) to 7 (Very true for me), with higher scores indicating greater risks for 
these two components. Although less commonly used than the INQ-15, this version of 
the measure has demonstrated comparable psychometric properties (Hill et al., 2014).   
Alpha equaled 0.88 for the perceived burdensomeness subscale and 0.72 for thwarted 
belongingness.   
Risk for Suicide.  The MINI was again utilized to assess current (past month) 
suicide risk and attempt history.  The MINI includes 11 items assessing a variety of 
suicide risk factors present within the past month:  (1) experience of an accident in which 
the individual intended to injure themselves or die, (2) hopelessness, (3) thoughts of 
being better off dead, (4) a desire to harm oneself, (5) thoughts about suicide, (6) 
difficulties controlling impulses to end one’s life, (7) presence of a suicide plan, (8) 
actions taken in preparation to injure or kill oneself, (9) past month non-suicidal self-
injury, (10) a past month suicide attempt, (11) a lifetime suicide attempt.  A score is 
obtained by summing the values from the endorsed items.  Scores can range from 0 (no 
risk) to 52 (high suicide risk).  The MINI suicidal risk index has been shown to predict 
suicidal behaviors over the course of one year (Roaldset, Linaker, & Bjørkly, 2012).   
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Covariates 
Depressive & Anxiety Symptom Severity.  The Depression, Anxiety, Stress Scale 
(DASS-21; Lovibond & Lovibond, 1995) is a 21-item self-report questionnaire designed 
to assess the unique symptoms of depression, anxiety, and stress.  Items are rated from 0 
(did not apply to me at all) to 3 (applied to me very much, or most of the time).  The 
Depression scale was utilized to assess the severity of dysphoria, hopelessness, 
devaluation of life, self-deprecation, lack of interest, anhedonia, and inertia experienced 
within the past week.  The Anxiety scale was utilized to assess the severity of irritability, 
agitation, difficulty relaxing, and impatience experienced within the past week.  
Depression and anxiety symptom severity were utilized as covariates to ensure that the 
severity of psychopathology was not a better explanation for higher rates of suicidal 
desire than was psychotropic medication usage.  The DASS has demonstrated adequate 
psychometric properties (Antony, Bieling, Cox, Enns, & Swinson, 1998).  The alpha 
coefficient was 0.90 for the depression subscale and 0.84 for the anxiety subscale.   
Borderline Personality Disorder (BPD) Symptom Severity.  The Borderline 
Evaluation of Severity Over Time (BEST; Pfohl et al., 2009) is a 15-item, self-report 
measure of past month BPD symptom severity.  Items 1 through 12 are rated from 1 (no 
distress) to 5 (extreme distress), and items 13 through 15 are rated from 1 (almost never) 
to 5 (almost always).  The BEST has demonstrated adequate reliability and validity 
(Pfohl et al., 2009).  BEST scores were included to account for severity of BPD symptom 
severity.  Internal consistency in our analysis was 0.83.   
Substance Use Severity.  The Drug Use Questionnaire (DUQ; Hien & First, 1991) 
is a 10-item, self-report questionnaire assessing frequency of alcohol and drug use over 
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the past year.  Item responses are summed, creating an overall score representative of 
past-year substance use frequency for various substances.  The overall score for 
substance use frequency did not include the frequency of nicotine use in this study.  The 
DUQ has demonstrated good convergent validity with structured interview diagnoses in 
association with relevant clinical outcomes (Lejuez, Bornvalova, Reynolds, Daughters, & 
Curtin, 2007).  Here again, DUQ scores were included to account for the impact of the 
severity of psychopathology.   
Demographics 
 Demographic covariates were determined empirically by testing for 
significant associations between the predictor and outcome variables and gender, race, 
age, education level, employment status, marital status, and total household income.   
Procedures 
All procedures were reviewed and approved by the relevant Institutional Review 
Boards prior to the onset of data collection.  Data was collected as part of a broader study 
examining risky behaviors among SUD patients (N = 226).  Inclusion criteria for the 
initial study included:  cocaine and/or alcohol dependence, a Mini-Mental Status Exam 
(MMSE; Folstein, Folstein, & McHugh, 1975) score of ≥ 24, and absence of current 
psychotic disorders.  In order to produce a sample with negligible withdrawal effects, 
eligible participants were recruited for participation no sooner than 72 hours from entry 
into the treatment facility. Additionally, patients were also required to undergo 
detoxification from an external source prior to entry into treatment, further reducing 
potential confounds related to withdrawal.  The initial study was completed over a total 
of three sessions.  All of the data used in the current study were collected in the first 
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session of the initial study, and data unrelated to the current study were collected in the 
remaining two sessions (e.g. heart rate variability, cortisol levels, and distress levels).  
One participant from the original study was not included in the current study due to lack 
of information regarding the use of psychotropic medication.   
Data Analytic Procedures 
In order to test our hypotheses, nine Analyses of Covariance (ANCOVAs) were 
conducted.  PB served as the outcome variable within three analyses, TB served as the 
outcome variable in three analyses, and suicide risk served as the outcome variable in the 
remaining three analyses.  Within all nine analyses, severity of psychopathology was 
accounted for by including depression, anxiety, BPD severity, and frequency of substance 
use as covariates.  Additionally, for analyses in which PB was the outcome variable, TB 
was included as a covariate.  For analyses in which TB was the outcome variable, PB was 
included as a covariate.  The use of psychotropic medication (none vs. 1+) served as the 
predictor variable for the first three analyses and the number of psychotropic medications 
(none or one vs. 2+) utilized served as the predictor variable for the second three 
analyses.  Finally, the use of an antipsychotic (vs. use of other psychotropics) served as 
the predictor variable for the final three analyses examining the association between 
antipsychotics and suicidal desire.  In the final analysis, only individuals currently 
prescribed one or more psychotropic medications were included. 
In an effort to increase specificity, an exploratory analysis consisting of nine 
ANCOVAs was conducted.  The use of an antidepressant (versus use of other 
psychotropics) served as our predictor in the first three analyses, the use of an anxiolytic 
served as the predictor in the second three analyses, and the use of a mood stabilizer 
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served as the predictor for the final three analyses.  Again, PB, TB, and suicide risk 
served as the outcome variables, and depression, anxiety, and BPD severity were 
included as covariates.   
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CHAPTER III 
RESULTS 
Examination of Distributions 
PB, TB, and suicide risk all exhibited significant skew and/or kurtosis and were 
thus rank transformed using Blom’s formula to better approximate a normal distribution.   
Selection of Covariates 
In order to determine the appropriate covariates to be included within analyses, a 
series of analyses of variance (ANOVA) were utilized to determine between group 
differences in PB, TB, and suicide risk for the demographic variables sex, race, 
employment status, and relationship status.  ANOVAs were also conducted to determine 
if significant differences in psychotropic medication use, number of psychotropic 
medications used, and antipsychotic use existed for continuous demographic variables 
(age, total family income, and education level).  Results indicated significant differences 
between the various statuses of employment for suicide risk (F (5, 213) = 2.67, p < 0.05) 
and educational levels for psychotropic medication use (F (9, 211) = 2.29, p < 0.05) and 
number of psychotropic medication used (F (9, 211) = 3.00, p < 0.01).  No other between 
group differences were significant.   
Next, a series of chi-square analyses were utilized to determine if significant 
differences in psychotropic medication use, number of psychotropic medications used 
and antipsychotic use existed for sex, race, employment status, and relationship status.  
Results indicated that gender (χ2(1, N = 222) = 16.24, p < 0.01) and race (χ2(4, N = 222) 
= 17.81,  p < 0.01) were significantly associated with psychotropic medication use.  
Additionally, gender (χ2(1, N = 222) = 9.12, p < 0.01) and race (χ2(4, N = 222) = 17.81, p 
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< 0.01) were significantly associated with number of psychotropic medications used.  No 
other chi-square analyses were significant.   
Finally, zero-order correlations were used to examine associations between 
continuous demographic variables (age, total family income, and education level) and 
TB, PB and suicide risk.  Results revealed significant correlations between education 
level and TB (r = 0.17, p < 0.05).  No other zero-order correlations were significant.   
In summary, depression, anxiety and BPD severity and frequency of substance 
abuse not including nicotine were included as covariates in all analyses.  Gender, race, 
and education level were included as covariates for all analyses involving psychotropic 
medication use and number of psychotropic medications used.  Education was also 
included in analyses involving PB, and employment status was included in all analyses 
involving suicide risk.   
Primary Analyses 
In order to test hypotheses, three series of ANCOVAs were conducted.  The first 
series of ANCOVAs assessed whether the use of psychotropic medication was associated 
with higher mean levels of TB, PB, and suicide risk.  Results revealed a statistically 
significant difference in suicide risk (F(9, 191) = 9.62, p < 0.01) between individuals 
utilizing one or more psychotropic medications and individuals not utilizing a 
psychotropic medication, accounting for gender, race, employment status, education 
level, and severity of psychopathology and substance use.  Results also revealed non-
significant differences in PB (F(9, 187) = 0.067, p = 0.80) and TB (F(9, 187) = 0.015, p = 
0.90) between individuals utilizing at least one psychotropic medication and individuals 
utilizing no psychotropic medications (Table 4).    
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The second series of ANCOVAs assessed whether the number of psychotropic 
medications was associated with higher mean levels of PB, TB, and suicide risk.  Results 
revealed non-significant differences in PB (F(9, 187) = 0.12, p = 0.73), TB (F(9, 187) = 
1.49, p = 0.22), and suicide risk (F(9, 191) =0.50, p = 0.48) between individuals utilizing 
one or no psychotropics and individuals utilizing two or more psychotropics (Table 5).  
The third series of ANCOVAs assessed whether antipsychotic use was associated 
with higher mean levels of PB, TB, and suicide risk relative to the use of other classes of 
psychotropics.  Results revealed a non-significant difference in PB (F(6, 89) = 1.29, p = 
0.26), TB (F(7, 88) = 0.50, p = 0.48), and suicide risk (F(6, 92) = 0.016, p = 0.90; Table 
6).  
Exploratory Analyses 
In an effort to increase specificity, exploratory analyses were conducted.  These 
analyses consisted of nine ANCOVAs, similar to the final three ANCOVAs used to test 
our hypotheses regarding the use of an antipsychotic, with the difference being that the 
predictor variable, antipsychotic use (versus other psychotropic medication), was 
replaced with either antidepressant use, anxiolytic use, or mood stabilizer use (versus 
other psychotropic medication use).  PB, TB, and suicide risk served as the outcome 
variables.  Again, depression, anxiety, and BPD severity, and substance use were 
included as covariates in addition to the demographics previously found to have either 
between group differences for or significant associations with TB, PB, and suicide risk.  
Additional demographic covariates were determined using both ANOVAs and Chi 
Square tests prior to testing any hypotheses.  Results indicated significant differences in 
total family income for anxiolytic use (F(10, 101) = 3.74, p  < 0.001) and a significant 
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association between gender and mood stabilizer use (χ2(1, N = 112) = 5.66, p = 0.017).  
Results revealed a significant difference in mean levels of PB (F(1, 91) = 4.59, p < 0.05) 
between individuals utilizing antidepressants and individuals utilizing another 
psychotropic other than an antidepressant.  All other exploratory analyses yielded non-
significant findings. 
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Table 4 
Mean Differences between Individuals Utilizing a Psychotropic and Not Utilizing a Psychotropic on Suicidal Desire and Risk. 
 No Psychotropic Use  Psychotropic Use     
 M SD  M SD  F p η2 
Burdensomeness 11.78 8.32  11.08 7.08  0.07 0.80 0.00 
Belongingness 17.76 7.22  18.53 7.56  0.02 0.90 0.00 
Suicide Risk 2.59 5.72  5.82 9.64  9.62* 0.002 0.05 
  
Note: * = significant at p < .05, ** = significant at p < .001; Perceived Burdensomeness: Interpersonal Needs Questionnaire-Perceived Burdensomeness subscale; Thwarted Belongingness: 
Interpersonal Needs Questionnaire-Thwarted Belongingness subscale.  Means and standard deviations reflect non-transformed Perceived Burdensomeness Thwarted Belongingness and 
Suicide Risk, but tests of between group differences are drawn from transformed totals. 
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Table 5 
Mean Differences between Individuals Utilizing 0 or 1 Psychotropic and 2 or More Psychotropics on Suicidal Desire and Risk. 
 Use of 0 or 1 
Psychotropic 
 Use of 2 or More 
Psychotropics 
    
 M SD  M SD  F p η2 
Burdensomeness 11.40 7.83  11.58 7.29  0.12 0.73 0.00 
Belongingness 18.05 7.42  18.57 7.31  1.49 0.22 0.01 
Suicide Risk 3.57 7.07  6.95 11.14  0.50 0.48 0.00 
 
Note: * = significant at p < .05, ** = significant at p < .001; Perceived Burdensomeness: Interpersonal Needs Questionnaire-Perceived Burdensomeness subscale; Thwarted Belongingness: 
Interpersonal Needs Questionnaire-Thwarted Belongingness subscale.  Means and standard deviations reflect non-transformed Perceived Burdensomeness Thwarted Belongingness and 
Suicide Risk, but tests of between group differences are drawn from transformed totals. 
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Table 6 
Mean Differences between Individuals Utilizing an Antipsychotic and Individuals not Utilizing an Antipsychotic on Suicidal 
Desire and Risk.   
 No Antipsychotic Use  Antipsychotic Use     
 M SD  M SD  F p η2 
Burdensomeness 10.42 6.46  12.80 7.47  1.29 0.26 0.01 
Belongingness 18.24 7.48  20.11 7.86  0.50 0.48 0.01 
Suicide Risk 5.54 9.44  6.82 10.76  0.02 0.90 0.00 
 
Note: * = significant at p < .05, ** = significant at p < .001; Perceived Burdensomeness: Interpersonal Needs Questionnaire-Perceived Burdensomeness subscale; Thwarted Belongingness: 
Interpersonal Needs Questionnaire-Thwarted Belongingness subscale.  Means and standard deviations reflect non-transformed Perceived Burdensomeness Thwarted Belongingness and 
Suicide Risk, but tests of between group differences are drawn from transformed totals. 
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Table 7 
Mean Differences between Individuals Utilizing an Antidepressant and Individuals not Utilizing an Antidepressant on Suicidal 
Desire and Risk.   
 No Antidepressant 
Use 
 Antidepressant Use     
 M SD  M SD  F p η2 
Burdensomeness 12.72 7.77  10.54 6.81  4.59 0.035 0.048 
Belongingness 18.67 6.93  18.49 7.79  1.21 0.27 0.013 
Suicide Risk 6.70 9.34  5.49 9.79  2.59 0.11 0.027 
 
Note: * = significant at p < .05, ** = significant at p < .001; Perceived Burdensomeness: Interpersonal Needs Questionnaire-Perceived Burdensomeness subscale; Thwarted Belongingness: 
Interpersonal Needs Questionnaire-Thwarted Belongingness subscale.  Means and standard deviations reflect non-transformed Perceived Burdensomeness Thwarted Belongingness and 
Suicide Risk, but tests of between group differences are drawn from transformed totals. 
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Table 8 
Mean Differences between Individuals Utilizing an Anxiolytic and Individuals not Utilizing an Anxiolytic on Suicidal Desire 
and Risk.   
 No Anxiolytic Use  Anxiolytic Use     
 M SD  M SD  F p η2 
Burdensomeness 11.42 7.36  9.86 5.98  0.15 0.70 0.002 
Belongingness 18.77 7.78  17.68 6.82  0.061 0.81 0.001 
Suicide Risk 5.87 10.05  5.63 8.17  2.96 0.089 0.031 
 
Note: * = significant at p < .05, ** = significant at p < .001; Perceived Burdensomeness: Interpersonal Needs Questionnaire-Perceived Burdensomeness subscale; Thwarted 
Belongingness: Interpersonal Needs Questionnaire-Thwarted Belongingness subscale.  Means and standard deviations reflect non-transformed Perceived Burdensomeness 
Thwarted Belongingness and Suicide Risk, but tests of between group differences are drawn from transformed totals. 
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Table 9 
Mean Differences between Individuals Utilizing a Mood Stabilizer and Individuals not Utilizing a Mood Stabilizer on Suicidal 
Desire and Risk.   
 No Mood Stabilizer 
Use 
 Mood Stabilizer Use     
 M SD  M SD  F p η2 
Burdensomeness 10.96 7.19  11.61 6.75  0.060 0.81 0.001 
Belongingness 18.18 7.53  20.05 7.74  0.019 0.89 0.000 
Suicide Risk 5.61 9.45  6.58 10.48  0.41 0.53 0.004 
 
Note: * = significant at p < .05, ** = significant at p < .001; Perceived Burdensomeness: Interpersonal Needs Questionnaire-Perceived Burdensomeness subscale; Thwarted Belongingness: 
Interpersonal Needs Questionnaire-Thwarted Belongingness subscale.  Means and standard deviations reflect non-transformed Perceived Burdensomeness Thwarted Belongingness and 
Suicide Risk, but tests of between group differences are drawn from transformed totals.
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CHAPTER IV 
DISCUSSION 
This study aimed to examine the relationship between psychotropic medication 
usage and suicidal desire and risk.  Specifically, this study aimed to indicate whether the 
use of psychotropic medication, use of multiple psychotropic medications, and usage of 
an antipsychotic were associated with heightened levels of PB, TB, and risk for suicide.  
Results were mostly inconsistent with hypotheses; however, results supported the 
hypothesis that the use of psychotropic medication would result in a higher overall risk 
for suicide.  Additional exploratory analyses also revealed that the use of an 
antidepressant resulted in lower levels of PB than the use of any other class of 
psychotropic medication. 
As expected, risk for suicide significantly differed between individuals utilizing 
psychotropic medication(s) and individuals not utilizing psychotropic medication. 
Individuals utilizing psychotropics exhibited higher mean levels for suicide risk than 
individuals not utilizing psychotropics (non-transformed means = 5.82 versus 2.59), 
suggesting that individuals utilizing a psychotropic are at an increased risk for suicide 
relative to individuals not utilizing a psychotropic, even after accounting for the severity 
of the psychopathology that prompted the prescription of the medication(s).  
The non-significant difference in levels of PB and TB as a result of both 
psychotropic medication use and use of multiple psychotropics may be due to the sample 
composition, as the majority of the sample for this study was comprised of individuals 
who identified as White/Caucasian and marginally consisted of more females than males.  
Furthermore, the majority of individuals utilizing psychotropic medications were 
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White/Caucasian females.  The negative stigma associated with the use of psychotropic 
medication may be diminished or even nonexistent for women and certain racial/ethnic 
groups.  Specifically, the use of psychotropic medications by white females may not be 
associated with a negative stigma among such individuals because of its prevalent use 
within this gender.  A study examining the trends in psychotropic medication use 
discovered that utilization of an antidepressant within females was twice the rate of that 
in males (Paulose-Ram, Safran, Jonas, Gu, & Orwig, 2007).  Furthermore, non-Hispanic 
white individuals had a higher utilization rate relative to non-Hispanic blacks and 
Mexican-Americans, specifically, non-Hispanic blacks and Mexican-Americans utilized 
antidepressants 55% and 67% less than non-Hispanic whites.   
The lack of significant findings may also be due to the measure of PB and TB 
utilized.  The questions within the INQ prompt participants to consider their feelings 
within a recent timeframe (i.e. “these days”), implying that responses reference feelings 
which were active in the here and now, rather than within their lifetime or even the recent 
past.  It is possible that participants’ levels of PB and TB may have decreased upon entry 
into the treatment facility, especially given the fact that participants were required to 
undergo detox for a period of time prior to entry into the facility.  This explanation is 
underscored by the finding of a significant difference in suicide risk between individuals 
utilizing a psychotropic and individuals not utilizing a psychotropic, as the MINI 
examines past moth and lifetime frequency; thus, suggesting that psychotropic 
medication use was related to suicide when assessed within a broader timeframe.  It is 
also possible that the relationship between psychotropic medication use and suicide is 
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independent of TB and PB, operating through different mechanisms not considered 
within the proposed model.   
Another possible explanation for the lack of significances may be the setting in 
which the study was conducted.  All participants within this study resided at a residential 
treatment facility during the study.  Psychotropic medication use was typical among 
participants, as 49.8% of participants utilized a psychotropic medication; thus, the use of 
a psychotropic medication may be considered more socially acceptable within this 
particular setting.  This explanation is analogous with Fife et al.’s (2012) finding that 
psychiatric and substance abuse outpatients displayed more favorable attitudes regarding 
the use of psychotropic medication relative to individuals never having utilized a 
psychotropic medication.   
 An additional interpretation of these results might be that the relationship 
between suicide risk and psychotropic medication is bidirectional.  It may be more likely 
that a psychotropic medication is frequently prescribed in response to an overt 
endorsement of suicide (e.g., a prior suicide attempt), whereas report of a broader 
vulnerability (i.e. TB or PB) may be less likely to prompt the prescription of psychotropic 
medication.  
 Although unexpected, levels of PB significantly differed among 
individuals utilizing antidepressants and individuals utilizing another type of 
psychotropic, with individuals utilizing antidepressants displaying lower mean levels of 
PB (10.54 Vs. 12.72).  This significant difference implies that individuals utilizing 
antidepressants experience reduced feelings of PB.  Further, these findings suggest that 
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the relationship between psychotropics and suicidality may not be explained by either the 
side effects or stigmas associated with such medication.   
 Findings from the current study should be considered within the context of 
their limitations.  As noted before, one such limitation was the sample composition.  The 
generalizability of our results to populations other than SUD inpatient populations is 
unclear.  Additionally, inter-rater reliability for the structured interviews utilized in this 
study was unavailable.  Future studies should replicate these procedures in various 
populations and establish inter-rater reliability for structured interviews.   
Despite these limitations, this study has significant scientific and clinical 
implications.  Scientifically, the data provide evidence that psychotropic medication use 
may increase an individual’s risk for suicide.  Furthermore, the study indicates a need for 
future research examining the mechanisms influencing the relationship between 
psychotropic medication and suicide. Clinically, the findings from this study may serve to 
increase awareness among prescribing physicians and clinicians, in turn prompting 
physicians and clinicians to perform routine suicide risk assessments for individuals 
utilizing psychotropic medication(s).   
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